{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T15:41:07Z","timestamp":1772552467043,"version":"3.50.1"},"reference-count":39,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000765","name":"University College London","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100000765","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Clovis Oncology, Inc.","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1136\/ijgc-2019-000623","type":"journal-article","created":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T12:07:26Z","timestamp":1572869246000},"page":"1396-1404","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, BRCA-mutated, high-grade ovarian cancer, and an update on safety"],"prefix":"10.1016","volume":"29","clinical-trial-number":[{"clinical-trial-number":"nct01482715","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01891344","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01482715","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01891344","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01078662","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02354586","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02855944","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02282020","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01891344","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01482715","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Rebecca S","family":"Kristeleit","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Oaknin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Ray-Coquard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Leary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith","family":"Balma\u00f1a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvette","family":"Drew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit M","family":"Oza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronnie","family":"Shapira-Frommer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan M","family":"Domchek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terri","family":"Cameron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lara","family":"Maloney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Goble","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenica","family":"Lorusso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan A","family":"Ledermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iain A","family":"McNeish","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2019-000623_bb0010","author":"Ferlay","year":"2018"},{"issue":"suppl 6","key":"10.1136\/ijgc-2019-000623_bb0015","doi-asserted-by":"crossref","first-page":"vi24","DOI":"10.1093\/annonc\/mdt333","article-title":"Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Ledermann","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2019-000623_bb0020","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2217\/fon-2017-0317","article-title":"Platinum or nonplatinum in recurrent ovarian cancer: that is the question","volume":"13","author":"Poveda","year":"2017","journal-title":"Future Oncol"},{"key":"10.1136\/ijgc-2019-000623_bb0025","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1038\/bjc.2013.389","article-title":"Deleterious BRCA1\/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions","volume":"109","author":"Moon","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1136\/ijgc-2019-000623_bb0030","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/nbt.2121","article-title":"Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors","volume":"30","author":"Wahlberg","year":"2012","journal-title":"Nat Biotechnol"},{"key":"10.1136\/ijgc-2019-000623_bb0035","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1158\/1535-7163.MCT-13-0803","article-title":"Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib","volume":"13","author":"Murai","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"10.1136\/ijgc-2019-000623_bb0040","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"Fong","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2019-000623_bb0045","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"10.1136\/ijgc-2019-000623_bb0050","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/jnci\/djq509","article-title":"Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2","volume":"103","author":"Drew","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1136\/ijgc-2019-000623_bb0055","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1158\/1078-0432.CCR-16-2796","article-title":"A phase I-II study of the oral PARP inhibitor rucaparib in patients with germline BRCA1\/2 mutated ovarian carcinoma or other solid tumors","volume":"23","author":"Kristeleit","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2019-000623_bb0060","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","article-title":"Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial","volume":"18","author":"Swisher","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2019-000623_bb0065","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"key":"10.1136\/ijgc-2019-000623_bb0070","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/1078-0432.CCR-13-2287","article-title":"Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas","volume":"20","author":"Pennington","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2019-000623_bb0075","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Cancer Genome Atlas Research Network","year":"2011","journal-title":"Nature"},{"key":"10.1136\/ijgc-2019-000623_bb0080","series-title":"Rubraca (rucaparib) tablets [summary of product characteristics]","year":"2019"},{"key":"10.1136\/ijgc-2019-000623_bb0085","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ygyno.2017.08.022","article-title":"Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: integrated analysis of data from Study 10 and ARIEL2","volume":"147","author":"Oza","year":"2017","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2019-000623_bb0090","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1136\/ijgc-2019-000623_bb0095","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","article-title":"The medical dictionary for regulatory activities (MedDRA)","volume":"20","author":"Brown","year":"1999","journal-title":"Drug Saf"},{"key":"10.1136\/ijgc-2019-000623_bb0100","unstructured":"NCI Term Browser CTCAE . Available: https:\/\/nciterms.nci.nih.gov\/ncitbrowser\/pages\/vocabulary.jsf?dictionary=CTCAE&version=4.03 [Accessed 19 Feb 2019]."},{"key":"10.1136\/ijgc-2019-000623_bb0105","series-title":"Zejula (niraparib) capsules [prescribing information]","year":"2017"},{"key":"10.1136\/ijgc-2019-000623_bb0110","series-title":"Zejula (niraparib) capsules [summary of product information]","year":"2019"},{"key":"10.1136\/ijgc-2019-000623_bb0115","series-title":"Lynparza (olaparib) [summary of product information]","year":"2018"},{"key":"10.1136\/ijgc-2019-000623_bb0120","series-title":"Lynparza (olaparib) tablets [prescribing information]","year":"2018"},{"key":"10.1136\/ijgc-2019-000623_bb0125","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2019-000623_bb0130","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2019-000623_bb0135","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S1470-2045(13)70240-7","article-title":"The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial","volume":"14","author":"Sandhu","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2019-000623_bb0140","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ygyno.2015.12.020","article-title":"Efficacy and safety of olaparib monotherapy in germline BRCA1\/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy","volume":"140","author":"Domchek","year":"2016","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2019-000623_bb0145","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1200\/JCO.2014.56.2728","article-title":"Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation","volume":"33","author":"Kaufman","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2019-000623_bb0150","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/annonc\/mdw133","article-title":"Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1\/2 mutation: a multistudy analysis of response rates and safety","volume":"27","author":"Matulonis","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2019-000623_bb0155","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2019-000623_bb0160","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s00432-008-0488-x","article-title":"Usefulness of third-line chemotherapy for women with recurrent ovarian, fallopian tube, and primary peritoneal cancer who receive platinum\/taxane regimens as first-line therapy","volume":"135","author":"Nishio","year":"2009","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1136\/ijgc-2019-000623_bb0165","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ejogrb.2012.10.003","article-title":"Advanced (>second) line chemotherapy in the treatment of patients with recurrent epithelial ovarian cancer","volume":"166","author":"Bruchim","year":"2013","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1136\/ijgc-2019-000623_bb0170","first-page":"424","article-title":"Effectiveness of third-line chemotherapy in recurrent ovarian cancer patients","volume":"36","author":"Yoshihama","year":"2015","journal-title":"Eur J Gynaecol Oncol"},{"key":"10.1136\/ijgc-2019-000623_bb0175","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3747\/co.2007.148","article-title":"Optimal chemotherapy treatment for women with recurrent ovarian cancer","volume":"14","author":"Fung-Kee-Fung","year":"2007","journal-title":"Curr Oncol"},{"key":"10.1136\/ijgc-2019-000623_bb0180","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.ygyno.2006.04.002","article-title":"Evaluation of the incidence of carboplatin hypersensitivity reactions in cancer patients","volume":"103","author":"Navo","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2019-000623_bb0185","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ygyno.2009.11.026","article-title":"Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial","volume":"116","author":"Markman","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2019-000623_bb0190","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/0959-8049(94)90489-8","article-title":"Hypersensitivity reactions to carboplatin given to patients with relapsed ovarian carcinoma","volume":"30","author":"Morgan","year":"1994","journal-title":"Eur J Cancer"},{"key":"10.1136\/ijgc-2019-000623_bb0195","article-title":"QUADRA: a phase 2, open-label, single-arm study to evaluate niraparib in patients (PTS) with relapsed ovarian cancer (ROC) who have received \u22653 prior chemotherapy regimens","volume":"36:(15_suppl):abstract 5514","author":"Moore","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2019-000623_bb0200","article-title":"Olaparib monotherapy versus (vs) chemotherapy for germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (PTS): phase III SOLO3 trial","volume":"37:(15_suppl):abstract 5506","author":"Penson","year":"2019","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24002986?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24002986?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2019-000623","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T22:19:15Z","timestamp":1753222755000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24002986"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":39,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S1048891X24002986"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2019-000623","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, BRCA-mutated, high-grade ovarian cancer, and an update on safety","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2019-000623","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2019 This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https:\/\/creativecommons.org\/licenses\/by\/4.0\/.","name":"copyright","label":"Copyright"}]}}